FDA Approves First Generic Versions of Aciphex

The FDA approved the first generic versions of Aciphex (rabeprazole sodium; Eisai) delayed-release tablets 20mg for the treatment of gastroesophageal reflux disease (GERD) in patients >12 years old.

Six companies have received FDA approval to market generic Rabeprazole: Dr. Reddy’s Laboratories, Kremers Urban Pharmaceuticals, Lupin, Mylan, Teva, and Torrent.

RELATED: Gastrohepatic Disorders Resource Center

Aciphex is a proton-pump inhibitor that works by decreasing the amount of acid made in the stomach to treat the symptoms of GERD (eg, heartburn, regurgitation of acid, and nausea). 

Aciphex is also used to treat Zollinger-Ellison syndrome, ulcers, and is used in combination with other medications to eliminate H. pylori.

For more information (888) 463-6332 call or visit FDA.gov.